RxDoctor Payments Data

Thomas Donnelly, MD

Pulmonary Disease · Aurora, CONPI 1255323895

Payments from drug & device makers

$379in general payments, 2019–2025

Across 19 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$117
  • Pulmonx Corporation$92
  • Takeda Pharmaceuticals U.S.A., Inc.$37
  • Inspire Medical Systems, Inc.$36
  • AstraZeneca$33
  • Sanofi$23
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$379 in reported general payments places this provider in the 30th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$80,590
Medicare patients
270
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,917
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$32,273
Breo ElliptaFluticasone/Vilanterol28$25,624
Spiriva RespimatTiotropium Bromide34$23,840
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$15,730
Advair HfaFluticasone Propion/Salmeterol44$14,974
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,333
SymbicortBudesonide/Formoterol Fumarate34$7,633
XareltoRivaroxaban11$6,006
Albuterol Sulfate HfaAlbuterol Sulfate172$3,145
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,506
Wixela InhubFluticasone Propion/Salmeterol16$1,504
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$996
BreynaBudesonide/Formoterol Fumarate14$487
Fluticasone Propionate15$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$117$74,27186 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$13$56,11399 claims
AstraZenecaBreztri Aerosphere, Symbicort$33$20,96645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →